Effect of DMARDs on Bone Structure and Strength in PsA Effect of DMARDs on Bone Structure and Strength in PsA

In what ways might DMARD treatment impact bone structure and strength in patients with psoriatic arthritis?Arthritis Research &Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Related Links:

Authors: Enciso-Vargas M, Alvarado-Ruíz L, Suárez-Villanueva AS, Macías-Barragán J, Montoya-Buelna M, Oceguera-Contreras E, Alvarado-Navarro A, Graciano-Machuca O Abstract Background: Psoriatic Arthritis (PsA) is a seronegative spondyloarthropathy frequently associated with psoriasis. Studies have shown different members of the KIR (Killer Immunoglobulin-like Receptor) gene family may act as potential susceptibility factors; however, data have been inconsistent or with a reduced sample size. Therefore, the objective of this investigation was to determine associations between KIR genes an...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Rheumatoid Arthritis (RA) has been increasingly associated with perturbations to the microbial communities that reside in and on the body (the microbiome), in both human and animal studies. To date, such studies have mainly focused on the microbial communities that inhabit the gut and oral cavity. Mounting evidence suggests that microbial DNA can be detected in the blood circulation using a range of molecular methods. This DNA may represent an untapped pool of biomarkers that have the potential to report on changes to the microbiome of distant sites (e.g., example, the gut and oral cavity). To this end, through amplificati...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
AbstractChronic inflammation, such as that present in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), leads to aberrations in bone remodeling, which is mediated by several signaling pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. In this light, pro-inflammatory cytokines are now clearly implicated in these processes as they can perturb normal bone remodeling through their action on osteoclasts and osteoblasts at both intra- and extra-articular skeletal sites. As a selective inhibitor of JAK1 and JAK3, tofacitinib has the potential to play a role in the mana...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
The long-term safety was assessed in patients with psoriatic arthritis who were treated with ixekizumab in three clinical trials (SPIRIT-P1/-P2/-P3).
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
AbstractPurpose of ReviewBimekizumab, a novel monoclonal antibody directed against both interleukin (IL)-17A and IL-17F, is in clinical development as a treatment for psoriasis and psoriatic arthritis. The purpose of this review is to highlight the roles of IL-17A and IL-17F in psoriatic inflammation as well as the clinical data on bimekizumab that has been reported to date.Recent FindingsPhase 2 efficacy results with bimekizumab have demonstrated high levels of rapid skin clearance in psoriasis patients, and high levels of joint disease improvement in psoriatic arthritis patients. Thus far, safety concerns have been limit...
Source: Current Dermatology Reports - Category: Dermatology Source Type: research
Conclusion: PsA is characterized by an increase in cardiovascular morbidity in relation with insulin resistance. Current treatments seem to improve this risk with a decrease in cardiovascular mortality in comparison with patients with plaque psoriasis but this requires confirmation in larger prospective studies.
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
AbstractAimsTo (1) determine the reliability and validity of the Bristol Rheumatoid Arthritis Fatigue scale (BRAF-NRS) in patients with psoriatic arthritis (PsA) and (2) examine possible clinical associations of worse fatigue in PsA.MethodsStudy phase 1: BRAF-NRS scale validation cohort. A consecutive cohort of 70 PsA patients was recruited to complete the 3-item BRAF-NRS and the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaires, alongside disease activity assessment. All patients also completed the BRAF-NRS questionnaire, 1  day later. Study phase 2: Identifying the potential c...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Myasthenia Gravis (MG) is an autoimmune disorder of neuromuscular transmission caused by circulating antibodies against different structures of the neuromuscular junction, such as AChR, muscle-specific kinase (MuSK) or related proteins (agrin, cortactin and low-density lipoprotein receptor-related protein 4) [1]. A role of T regulatory cell abnormalities has also been proven in MG pathogenesis [2]. The clinical hallmark of MG is fluctuating muscular weakness and fatigability on sustained repeated activity [1].
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Case report Source Type: research
ConclusionThe ILAR Treatment Recommendations for PsA intends to serve as reference for the management of PsA in the Americas and Africa. This paper illustrates the experience of an international working group in adapting existing recommendations to a resource-poor setting. It highlights the need to conduct research on the management of PsA in these regions as data are currently lacking.Key Points•The paper presents adapted recommendations for the management of psoriatic arthritis in resource-poor settings.•The ADAPTE process was used to adapt existing GRAPPA and EULAR recommendations by collaboration with practic...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
ConclusionsThe 5- and 6-point investigator global assessments, which are the most widely used investigator global assessments in registered clinical trials, have less evidence for measurement properties as compared with the Lattice System-Physician Global Assessment, professional-Simplified Psoriasis Index, and the Product of the Investigator Global Assessment and Body Surface Area. However, all instruments lack evidence for content validity and feasibility. Further validation studies of investigator global assessments and patient global assessments are required to recommend the best global measure for psoriasis clinical trials.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
More News: Arthritis | Health | Psoriatic Arthritis | Rheumatology